DarioHealth (Formerly Known As LabStyle Innovations)
Gibor Sport Tower
7 Menachem Begin Street
About DarioHealth (Formerly Known As LabStyle Innovations)DarioHealth Corp. (NASDAQ: DRIO) creates innovative mobile and digital tools that empower and engage users to lead healthier lives. DarioHealth’s “Real time. Real data. Real people” approach and strategy is positioning the company as a major player in the mHealth industry; an industry currently worth $10B and expected to reach $31B by 2020*. DarioHealth’s flagship product, the Dario™ Smart Diabetes Management Solution, is a platform for diabetes management that combines an all-in-one blood glucose meter, native smart phone app (iOS & Android), website portal and a wide variety of treatment tools to support more proactive and better informed decisions by users living with diabetes, their doctors and healthcare systems.
The Dario Smart Diabetes Management Solution was granted U.S. FDA marketing clearance in December 2015 and is set to launch in the current quarter in the U.S. – the largest market in the world for glucose monitoring. LabStyle has been granted patents, and is pursuing additional applications - in multiple areas covering the specific processes related to blood glucose level measurement, as well as more general methods for rapid body fluids testing using mobile devices and cloud-based services. Dario™ is currently available in the UK, New Zealand, Netherlands, Australia, Israel, Canada, Belgium and Italy. Dario received reimbursement coverage in the UK, Australia, Israel, Italy and Canada. Sequential quarterly revenues are growing rapidly, reflecting strong market adoption.
CEO: Erez Raphael
CFO: Zvi Ben-David
125 articles with DarioHealth (Formerly Known As LabStyle Innovations)
DarioHealth Reports Improvement in Glycemic Outcomes With Key Diabetes Findings at the American Diabetes Association's 79th Scientific Sessions
Digital Therapeutics leader DarioHealth caps off successful week at the ADA with Two Studies Presenting New Real-World Data in the Field of Diabetes
Functional Medicine Center of Fort Collins, in Fort Collins, CO will incorporate Dario's digital diabetes platform to its health and wellness improvement programs
DarioHealth to Present New Evidence of Digital Therapeutics Benefits at 2019 American Diabetes Association Conference
Outcomes of several new studies to be released, demonstrating improved life with diabetes.
DarioHealth Corp. announced the pricing of an underwritten public offering of 4,855,341 shares of common stock at a price to the public of $0.60 per share and pre-funded warrants to purchase 7,175,525 shares of common stock at a price to the public of $0.5999 per pre-funded warrant for aggregate gross proceeds of approximately $7,200,000, before underwriting discounts and offering expenses.
Global digital therapeutics innovator DarioHealth Corp. reported record financial and operational results for the first quarter ended March 31, 2019.
Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: DRIO) today announced it will release its first quarter 2019 results on Monday, May 13, and host a conference call the same morning at 9:00 am EDT.
DarioHealth's mission is to support people with diabetes and other chronic conditions in the U.S. and around the world.
New version V4.2.0 is a testament to Dario's relentless commitment to patients with chronic conditions.
DarioHealth Signs Leading Functional Medicine Clinic to DarioEngage™ Remote Digital Diabetes Platform
The 'Per Engaged Member Per Month' (PEMPM) model is value-driven, simple and effective to cover the needs of providers and their patients
DarioHealth Granted License by Health Canada to Sell Dario Smart Glucose Meters for Lightning® Connector Enabled iPhones
Significant expansion of Dario's Canadian market opportunity to include iPhone 7, 8, and iPhone X user
Earnings Discussion and Business Update Scheduled for 9:00 am EDT
DarioHealth Signs National Distribution Deal in the U.S. With Better Living Now for Its Digital Health Products
BLN will purchase DarioHealth's products including the Dario smart glucose meter and test strips for distribution to its customers.
DarioHealth to Offer Diabetes Content and Coaching to Patients in Canada in Collaboration With LMC Healthcare, Canada's Largest Diabetes and Endocrinology Specialist Care Provider
DarioHealth's Digital Diabetes Content and Coaching, powered by LMC, to be made available across Canada starting in Q12019
Earnings and business update call scheduled for 9:00 am ET today
DarioHealth's Digital Diabetes Platform to be Made Available to 4.6 Million Customers at Giant Eagle, One of America's Largest Supermarket Chains
Millions of Customers Will Be Able to Sign Up for Online Education and Rewards through the DarioHealth Blood Glucose Monitoring System and Smartphone Application. [12-November-2018] CAESAREA, Israel , Nov. 12, 2018 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today it h
DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it will release its third quarter 2018 results on Tuesday, November 13, and host a conference call the same morning at 9:00am EDT
DarioHealth's Digital Health Blood Glucose Monitoring System Compatible With New iPhone XS and XS Max
Analyst estimates 75-80 Million iPhone Shipments in 2H 2018
DarioHealth Appoints Glen D. Moller, Healthcare Executive, Investor and Former CEO of ArroHealth, to Its Board of Directors
DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, announced today that Glen Moller has joined the Company's Board of Directors.
Call to review recent fundraise, expected accelerated growth, and introduce new President and new Chairman
DarioHealth Appoints Olivier Jarry, Former Head of Diabetes Care at Bayer and Executive at Novartis and Bristol-Myers-Squibb, as President and Chief Commercial Officer
DarioHealth Corp. announced today that Olivier Jarry, a prominent global life sciences and consumer health executive, has joined the Company as President and Chief Commercial Officer.